EUCTR2022-003107-15-BG进行中（未招募）1 期
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,902
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adult participants = 18 years old at the time of signing the informed consent form.
- •2. Patients hospitalised with viral lung infection.
- •3. Hypoxaemia requiring treatment with supplemental O2
- •Hypoxaemia is defined as:
- •SpO2 . 90% OR
- •SpO2 . 92% AND one or both of the following:
- •Radiographic infiltrates by CXR/CT compatible with viral lung infection
- •per investigator judgement.
- •Use of accessory muscles of respiration or RR > 22.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1451
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1451
排除标准
- •1. Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or pulmonary sepsis. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant’s condition.
- •2. Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.
- •3. Ongoing IMV/ECMO at randomisation.
- •4. The following malignancies:
- •- Solid tumours with metastases (Stage IV).
- •- Lymphoma/leukaemia not in complete remission.
- •- Malignancies treated with chemotherapy and/or immunomodulatory
- •drugs within the past 2 months.
研究者
相似试验
招募中
3 期
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease with a History of ExacerbationsCOPDJPRN-jRCT2041230113Ageishi Yuji55
招募中
1 期
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).Severe viral lung infectionsMedDRA version: 21.1Level: PTClassification code 10001053Term: Acute respiratory failureSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-003107-15-DKAstraZeneca AB2,902
尚未招募
3 期
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).J129 Viral pneumonia, unspecifiedViral pneumonia, unspecifiedJ129PER-008-23AstraZeneca AB
尚未招募
3 期
A Phase III, Multicentre, Randomised, Double-blind, Chronic dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)J449 Chronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease, unspecifiedJ449PER-014-23AstraZeneca AB
进行中（未招募）
1 期
Study to assess efficacy, safety, and tolerability of MEDI3506 in symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 21.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-003771-34-FRAstraZeneca AB1,272